ArticleInternational medical case reports journal2025
Splenectomy for Primary Sjögren's Syndrome Associated with Massive Splenomegaly: Two Case Reports.
Article in International medical case reports journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary Sjögren's syndrome (pSS) is an autoimmune disease characterized by exocrine glands involving mainly the lacrimal and salivary glands. Splenomegaly from pSS is a rare clinical feature unless the pSS is complicated by lymphoma. Splenectomy could exclude malignant lymphoma, reduce the risk of spontaneous spleen rupture and remove hypersplenism to improve pancytopenia. Case Presentation: We reported the case of a 49-year-old female patient who was diagnosed with pSS according to dry mouth, dry eyes, splenomegaly, multiple positive autoantibodies, positive Schirmer's test and biopsy of labial gland with decreased number of acini and focal lymphocytic infiltration. Due to hematological involvement and liver dysfunction repeatedly, the pSS patient was admitted to the hospital and treated with glucocorticoids, immunosuppressants and hepatoprotective drugs. However, the pancytopenia failed to improve. Considering pancytopenia of the pSS patient caused by massive splenomegaly, splenectomy was recommended to the patient. The hematological involvement was significantly improved after splenectomy. Besides, another 46-year-old woman with a similar clinical manifestation was diagnosed with pSS complicated by massive splenomegaly, however, the patient refused to undergo the splenectomy. Conclusion: Splenectomy may be an effective treatment of pSS complicated by massive splenomegaly resulting in hematological involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.